Skip to main content

Septerna

Septerna Inc is an American clinical-stage biopharmaceutical enterprise focused on discovering and developing oral small molecule drugs targeting G protein-coupled receptors (GPCRs). The company utilizes its proprietary Native Complex Platform to isolate and stabilize functional GPCR targets, advancing pipeline candidates for endocrinology, immunology, and metabolic disorders. Principal revenue is driven through research collaboration upfront fees, clinical milestone payments, and development capital raised ahead of commercialization. Core end markets encompass endocrinology specialty clinics, immunology research centers, and biopharmaceutical partners globally. Septerna holds an innovative position in the biopharmaceutical sector for structure-guided GPCR small molecule drug discovery. The company is headquartered in South San Francisco, California, and its common stock trades on the Nasdaq Global Market.

3 of the funds FundTelligence covers report a position in Septerna.

Legal name
SEPTERNA
Sector
Health Care
Country
United States
Funds holding it
3

Funds holding Septerna

Loading...